Showing results (121-130 of 1,586) with videos related to
Sort By:
Pageof 159
AIDS (London, England)|March 1, 1994
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)J W Mulder, D A Cooper, L Mathiesen, et al.AIDS (London, England)|August 1, 1991
The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative GroupD A Cooper, C Pedersen, F Aiuti, et al.Journal of Human Virology|April 9, 1999
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparationsP Hermans, N Clumeck, O Picard, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infectionJulio Montaner, Patrick Yeni, Nathan N Clumeck, et al.Journal of Clinical Epidemiology|November 1, 1996
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study GroupA N Phillips, A Lazzarin, J Gonzales-Lahoz, et al.AIDS (London, England)|March 15, 1997
Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study GroupP Hermans, J Lundgren, B Sommereijns, et al.European Journal of Epidemiology|March 1, 1987
Seroepidemiological study on sexually transmitted diseases and hepatitis B in African promiscuous heterosexuals in relation to HTLV-III infectionP Van de Perre, N Clumeck, M Steens, et al.The New England Journal of Medicine|August 17, 1995
A controlled trial of zidovudine in primary human immunodeficiency virus infectionS Kinloch-De Loës, B J Hirschel, B Hoen, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in EuropeG Moyle, A Pozniak, M Opravil, et al.Attachment & Human Development|November 16, 2001
The development of attachment in separated and divorced families. Effects of overnight visitation, parent and couple variablesJ Solomon, C GeorgePageof 159